Validating N-Myristoyltransferase Inhibitor as a Novel Payload Class for ADCs: Exploring Myricx Bio’s Pre-Clinical Efficacy Studies with NMTi as Payload Platform
Time: 12:30 pm
day: Conference Day One
Details:
- N-Myristoyltransferase (NMT) as a drug target in cancer
- Development of NMT inhibitors (NMTi) as a Novel Payload Class for ADCs: case studies with NMTi-ADCs targeting B7-H3, TROP2 and HER2
- Advancing Myricx Bio’s NMTi-ADC pipeline for the treatment of solid tumors
